Boston, MA 02/07/2014 (wallstreetpr) – Gilead Sciences, Inc. (NASDAQ:GILD), the Foster City, CA-based biopharmaceutical company recently reported its fourth quarter results for 2013. It also announced its full EPS for 2013. With both of the results being reported as very good, Gilead Sciences should ideally have reported jump in prices.
Unfortunately, it did not happen as investors chose to focus on the lowering of value of GILD because there were no forecasts for the new Hepatitis-C drug, by Sovaldi.
Analysts such as ISI Group indicate that the lack of numbers or guidance with respect to Sovaldi has indeed been a disappointment.
Gilead Sciences, Inc. (NASDAQ:GILD) according to ISI Group, is viewed by investors as a conservative player and the lack of Solvadi sales guidance does give room for interpretation. Additionally, the announced operating expenses for 2014 do appear to be on a much higher side in comparison to investor expectations.
The intriguing factor, which has set the downward trend is the position Sovaldi currently holds with Gilead Sciences, Inc.(NASDAQ:GILD),
Does, the lack of sales figures indicate that the risks are higher as Sovaldi is likely to see a drop in the numbers, before the actual launch of Sovaldi/ledispavir later this year? Investors are interested in answers, to why GILD has taken a different perspective on Sovaldi.
Other analysts such as Elliot Favus indicate that Gilead Sciences, Inc. (NASDAQ:GILD) sell is a better position to hold for investors as there is too high expectations around the launch of Sovaldi. Besides, the profile of the shareholder currently invested in Gilead stock is too generalized. Their interpretation and the significance of the Hepatitis-C drug may be limited. Therefore, the overall future for this drug too would be diverse and not as focused as it was with the shareholder profiles of earlier.
Fourth quarter results for Gilead reported higher product sales and estimates being beaten. The full year EPS for 2014 reported strong performance.
